Search Results

Multiple Units at Tianwan Nuclear Power Plant Go Live with Self-Developed EPM System

On August 31, the EPM system, a production management platform independently developed by China National Nuclear Power (CNNP), was officially launched at Units 3, 4, 7, and 8 of Tianwan Nuclear Power Plant. This launch marks a new stage of standardized management and control for Jiangsu Nuclear Power's production management, and also provides a practical example from Tianwan Nuclear Power Plant for CNNP's digital transformation. The EPM system is a new-generation nuclear power plant production management system independently developed by CNNP with fully independent intellectual property rights. Designed to meet the operational needs of nuclear power plant field operations, the system integrates business processes such as planning, operations, maintenance, equipment, and safety permits, unifies plant-wide work execution standards, and achieves closed-loop control across the entire production management chain. The system covers...

2026-09-01

World's First 14,000-Ton-Class Ring Crane Rolls Off Production Line, Capable of Supporting Full-Module Lifting for HPR1000 2.0

Recently, XCMG's world's first 14,000-ton-class ring crane officially rolled off the production line. Su Zimeng, President of China Construction Machinery Association; Wang Guohua, Member of the Party Committee and Vice President of Sinopec Engineering (Group) Co., Ltd., as well as Party Secretary and General Manager of its Lifting and Transportation Company; and Yang Dongsheng, Chairman of XCMG Group and XCMG Machinery and Party Secretary, attended the launch ceremony. Xia Dechang, General Manager and Party Secretary of XCMG Crane Machinery Division, announced the successful rollout of the equipment. According to reports, the 14,000-ton-class ring crane was developed to meet the lifting needs of ultra-large and ultra-heavy equipment in major projects such as nuclear power, petrochemical, and marine engineering, with a focus on serving integrated lifting scenarios for large modules. The equipment achieves full-industry-chain...

2026-08-29

New tooling at Russia's Rostov NPP cuts filter maintenance time to two days

On August 28, local time, Russia's Rostov Nuclear Power Plant announced that its engineering and technical personnel have developed and put into operation a set of specialized tooling for the maintenance of filters in the ball-type pre-filter system (SShO) of the turbine hall, significantly reducing the time required for equipment maintenance preparation and overhaul. Rostov NPP is part of Rosenergoatom, the electric power division of Russia's State Atomic Energy Corporation (Rosatom). The filters targeted by this improvement weigh over one ton each and require crane assistance for movement, but the existing fixed cranes on site cannot directly cover the equipment locations. To address this issue, the maintenance preparation and implementation department...

2026-08-30

CNNC Changchun Nuclear Medicine Base Obtains Production License

On August 28, the Jilin Provincial Drug Administration approved and issued the "Radiopharmaceutical Production License" to Changchun Atomic Hi-Tech Pharmaceutical Co., Ltd. (hereinafter referred to as "Changchun Hi-Tech"), a subsidiary of Atomic Hi-Tech under China Isotope & Radiation Corporation (CIRC). The acquisition of this license marks that Changchun Hi-Tech is now fully qualified for the production of technetium-labeled drugs. Radiopharmaceuticals are characterized by short half-lives, high transportation requirements, and strict time sensitivity. Long-distance transportation not only increases transportation and time costs but also poses greater challenges to the stability and timeliness of clinical medication. With the production qualification, Changchun Hi-Tech will be able to complete the production and distribution of technetium-labeled drugs locally in Jilin Province, which will help improve the clinical use of nuclear medicine in the Northeast region...

2026-08-29

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

KHNP Advances Nuclear Process Heat-Based Hydrogen Production Ecosystem

Korea Hydro & Nuclear Power (KHNP) held a preparatory meeting in Daejeon on August 26 to establish an advisory body for building the Korean solid oxide cell industrial ecosystem, and discussed R&D strategic alliances and industry-academia-research cooperation frameworks. The collaboration will bring together industry, academia, and research institutions, including the Korea Institute of Ceramic Engineering and Technology (KICET). KHNP plans to use the advisory body as a platform to connect R&D, demonstration, and commercialization, promoting the self-reliance of Korean solid oxide cell (K-SOC) related technologies. According to the meeting agenda, KHNP will serve as the lead enterprise, proposing technology development directions needed for demonstration applications and commercialization; the Korea Institute of Ceramic Engineering and Technology will play a supporting role in supplying core industrial technologies.

2026-08-27

Lancaster University in the UK receives EPSRC funding to study antimatter production in intense laser pulses

Christopher Arran, a lecturer at Lancaster University and the Cockcroft Institute in the UK, has recently been awarded a three-year New Investigator Award from the UK Engineering and Physical Sciences Research Council (EPSRC) to study electron-positron pair production in the extremely intense electromagnetic fields of high-power lasers. The research focuses on matter-antimatter production processes under intense laser pulse conditions. Similar interactions are believed to exist in extreme cosmic environments, such as near pulsars and black hole accretion disks. Previously, such interactions had only been measured at large particle accelerator facilities such as Stanford University and the European Organization for Nuclear Research (CERN), but the electric and magnetic field strengths used in those experiments were far weaker than the strong-field conditions achievable with current high-power lasers.

2026-08-26

Two production lines at radiopharmaceutical plant in Russia's Kaluga Region enter trial production

Rosatom recently announced that two production lines at its modern radiopharmaceutical manufacturing facility in the Kaluga Region have entered trial production. The facility, built in accordance with the Eurasian Economic Union's international Good Manufacturing Practice (GMP) standards, is equipped with high-level production equipment and is designed to supply safe, quality-controlled radiopharmaceuticals to the market. According to reports, Rosatom's subsidiary enterprises currently produce more than ten registered diagnostic and therapeutic radiopharmaceuticals, involving isotopes such as iodine-123, iodine-131, technetium-99m, and samarium-153. The new plant's production plan is based on the demand for radioisotope products from Russian medical institutions through 2030. The company...

2026-08-26

Novartis Files Localized Production Application in China for Lutetium [177Lu] Vipivotide Tetraxetan

On August 24, information on the website of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration showed that Novartis' nuclear medicine product Lutetium [177Lu] Vipivotide Tetraxetan had a localized production application submitted in China. On the same day, two indications for the drug were proposed for priority review, and the relevant review matters may correspond to this localized production application. Lutetium [177Lu] Vipivotide Tetraxetan, namely 177Lu-PSMA-617, is a radioligand therapy (RLT) drug acquired by Novartis following its acquisition of Endocyte. The drug consists of a small-molecule compound targeting prostate-specific membrane antigen (PSMA) conjugated to the therapeutic radionuclide Lutetium-177. Upon entering the bloodstream, the drug binds to prostate cancer cells expressing PSMA, and...

2026-08-25

Phase I of Jinjiang Ruisi Ke Particle Therapy Equipment Production Base Fully Operational

Recently, Phase I of the Ruisi Ke Advanced Particle Therapy Equipment Production Base for tumors, located in Dongshi Town, Jinjiang, Fujian, has been fully put into operation, marking new progress in the life and health industry sector of Quanzhou South Wing National High-Tech Zone. As the first launch project in the local effort to build the "China Nuclear Medicine Valley," this project is accelerating the clustering of the nuclear medical equipment industry chain. It is understood that all four production workshops of Phase I of the Ruisi Ke production base have commenced operations, with a total floor area of nearly 30,000 square meters. Inside the workshops, relevant personnel are performing precision machining on core components of the proton therapy system. The base possesses research and development, production, and testing capabilities for proton therapy systems and boron neutron capture therapy systems, making it one of the few...

2026-08-24

Beijing's First Second-Generation High-Temperature Superconducting Tape Mass Production Line Project Approved

Recently, the second-generation high-temperature superconducting tape R&D and production project invested in by Energy Singularity Superconducting Technology (Beijing) Co., Ltd., a wholly-owned subsidiary of Energy Singularity, was officially approved for project initiation in the Daxing section of the Airport Economic Zone. Once completed and put into operation, the project will establish Beijing's first mass production line for second-generation high-temperature superconducting tape. According to reports, the project plans to build three production lines for rare-earth barium copper oxide (ReBCO) high-temperature superconducting tape based on the pulsed laser deposition (PLD) process route, achieving an annual output of 1,200 kilometers of high-temperature superconducting tape in the 12 mm width specification. High-temperature superconducting tape is a key raw material for manufacturing high-temperature superconducting magnets. In tokamak devices, high-temperature superconducting tape accounts for approximately...

2026-08-24

Atom High-Tech Adds New Radiopharmaceutical Production Base in Changchun

The Jilin Provincial Medical Products Administration issued a public notice on August 21 stating that, in accordance with the Drug Administration Law of the People's Republic of China, the Regulations on the Administration of Radiopharmaceuticals, the Measures for the Supervision and Administration of Drug Production, and other relevant provisions, following on-site inspection and review approval, it intends to issue the Radiopharmaceutical Production License to Changchun Atom High-Tech Pharmaceutical Co., Ltd. The public notice period is 5 working days, subject to public supervision. The notice information shows that the registered address of Changchun Atom High-Tech Pharmaceutical Co., Ltd. is located at No. 770 Shengye Road, Beihu Science and Technology Development Zone, Changchun City, Jilin Province, and the proposed production address for the license is consistent with the registered address. The proposed production scope for this license is small-volume injections for in vivo radiopharmaceuticals, involving products such as Sodium Pertechnetate [99mTc] Injection, Technetium [99mTc] Methylenediphosphonate Injection, Technetium [99mTc] Methoxyisonitrile Injection, Technetium [99mTc] Pentetate Injection, Technetium [99mTc] Ethyl Cysteinate Dimer Injection, and Technetium [99mTc] Etifenin Injection.

2026-08-24

Texas A&M University Develops Rio Red Grapefruit Through Radiation Mutagenesis, Now Accounting for About 75% of Texas Production

In 1984, researchers at Texas A&M University used radiation mutagenesis to develop the Rio Red grapefruit. Forty-two years later, this variety has become the dominant cultivar in Texas's grapefruit industry, accounting for approximately 75% of the state's total grapefruit production. The Rio Red grapefruit is distinguished by its vibrant pink flesh, as well as its greater cold tolerance and higher yields compared to other grapefruit varieties. These traits have facilitated its widespread adoption across Texas growing regions, gradually establishing it as a representative grapefruit variety in the local market. Grapefruit itself was not originally a product of artificial breeding. The earliest known grapefruit seedlings appeared in Barbados in the 18th century, resulting from a cross between the Jamaican sweet...

2026-08-22

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

IsoEnergy and DISA Complete Transaction to Launch U.S. Uranium Recovery and Production Company DISA Uranium

On August 19, IsoEnergy Ltd. and DISA Technologies, Inc. announced the completion of their previously disclosed transaction to form DISA Uranium Corporation. The new company is positioned as a technology-driven U.S. uranium enterprise, aiming to strengthen domestic uranium supply and serve the growing demand for domestically sourced nuclear fuel. Under the definitive agreement, IsoEnergy transferred its portfolio of permitted and previously producing conventional uranium assets in Utah, U.S., to DISA Uranium in exchange for 1,677,350 common shares of DISA Uranium. The asset portfolio includes the Tony M Mine, Daneros Mine, Rim Mine, Sage Plain Project, and Flatiron Project. Upon completion of the transaction...

2026-08-20